Surface De-PEGylation Controls Nanoparticle-Mediated siRNA Delivery In Vitro and In Vivo
Summary
Surface PEGylation of nanoparticles (NPs) improves circulation time and tumor accumulation but also hinders intracellular delivery, creating the "PEG dilemma" for siRNA therapeutics. While stimuli-responsive de-PEGylation strategies exist, they add complexity to NP design and synthesis. A tunable, serum albumin-mediated de-PEGylation strategy that avoids complex stimuli-responsive chemistry could balance long circulation with effective. ### Nanoparticle Properties | Parameter | Result | |---------------|------------| | Size (DMF) | ~60-70 nm | | Zeta potential (neutral lipid-PEGs) | ~+8 mV | | Zeta potential (anionic lipid-PEGs) | ~−7 mV | | siRNA.
Component: Nanoparticle Core; Description: PLGA (poly(lactide-co-glycolide)) polymer; solid core containing cationic lipid/siRNA complexes
Component: Cationic Lipid; Description: G0-C14 (epoxytetradecane-modified PAMAM generation 0 dendrimer) — forms nanocomplexes with siRNA
Component: Surface Coating; Description: Lipid-PEG (polyethylene glycol-lipid conjugates; PEG MW = 2 kDa) — self-assembles on NP surface via hydrophobic interactions
Component: Lipid-PEG Types Tested (8 total); Description: • Neutral: DMG-PEG (C14:0), DPG-PEG (C16:0), DSG-PEG (C18:0), Ceramide-PEG (C16:1, unsaturated)<br>• Anionic: DMPE-PEG (C14:0), DPPE-PEG (C16:0), DSPE-PEG (C18:0), DOPE-PEG (C18:1, unsaturated)
Component: siRNA; Description: Luciferase siRNA (siLuc) targeting firefly luciferase; fluorophore-labeled variants (DY547, DY647, DY677) for tracking
Component: Nanoparticle Properties; Description: • Size: ~60-70 nm (with DMF as solvent)<br>• Zeta potential: +8 mV (neutral lipid-PEGs) or −7 mV (anionic lipid-PEGs)<br>• siRNA encapsulation: ~50-60%<br>• Surface lipid-PEG: ~35-40 μg/mg PLGA
Component: Cell Lines; Description: • Luc-HeLa (firefly luciferase-expressing HeLa) — target cells<br>• RAW264.7 — macrophage cells (MPS clearance)
Component: Mouse Models; Description: • C57BL/6 (PK studies)<br>• Athymic nude mice with subcutaneous Luc-HeLa xenograft
Parameter: NP Preparation; Details: Self-assembly nanoprecipitation: siRNA + G0-C14 in DMF → added to lipid-PEG aqueous solution → stirring → washing; DMF chosen for smallest size
Parameter: Lipid-PEG Quantification; Details: Barium iodide-PEG complexation; absorbance at 535 nm
Parameter: Dissociation Kinetics; Details: NPs incubated in PBS + 4% BSA (or FBS, or PBS alone) at 37°C; ultracentrifugation; residual lipid-PEG quantified at time points; first-order dissociation model fitting
Parameter: In Vitro Silencing; Details: Luc-HeLa cells; NP(siLuc) at 1-50 nM siRNA; 24 h transfection; 48 h recovery; Steady-Glo luciferase assay; AlamarBlue for cell number; IC₅₀ calculated
Parameter: Cellular Uptake; Details: DY547-siRNA NPs; Luc-HeLa or RAW264.7; 3-24 h; fluorescence microscopy; ImageJ quantification
Parameter: Pharmacokinetics; Details: C57BL/6 mice; IV injection of DY647-siRNA NPs or naked siRNA; blood collection over time; fluorescence measurement; t₁/₂ and AUC calculated
Parameter: Biodistribution; Details: Luc-HeLa xenograft; IV injection of DY677-siRNA NPs or naked siRNA; 24 h harvest; Syngene PXi imaging; organ/tumor fluorescence quantification
Parameter: In Vivo Silencing; Details: Luc-HeLa xenograft; daily IV injection of NP(siLuc) or naked siLuc (1.2 mg/kg) for 3 consecutive days; bioluminescence imaging (D-luciferin); tumor lysate luciferase quantification (Steady-Glo, BCA)
Parameter: Controls; Details: Naked siRNA; PLGA/G0-C14 siRNA NPs without PEGylation; Lipofectamine 2000
Parameter: Sample Sizes; Details: In vivo: n=3-4 per group
Parameter: Statistical Tests; Details: Two-tailed Student's t-test; P < 0.05 significant
Analysis Category: Nanoparticle Characterization; Methods: DLS (size, zeta potential); TEM (morphology); Lipid-PEG quantification (barium iodide method)
Analysis Category: Dissociation Kinetics; Methods: Barium iodide-PEG complexation; absorbance at 535 nm; first-order kinetics fitting; k_d and t₁/₂ calculated
Analysis Category: In Vitro Silencing; Methods: Steady-Glo luciferase assay (Promega); AlamarBlue cell viability; IC₅₀ (Phoenix WinNonlin)
Analysis Category: Cellular Uptake; Methods: Fluorescence microscopy (Zeiss Axiovert 200); Fiji/ImageJ analysis; Hoechst 33342 nuclear stain
Analysis Category: Pharmacokinetics; Methods: Blood sampling; fluorescence measurement (BioTek microplate reader); standard curve; t₁/₂ and AUC
Analysis Category: Biodistribution; Methods: Syngene PXi imaging system; organ fluorescence quantification; % injected dose per gram tissue
Analysis Category: In Vivo Imaging; Methods: Syngene PXi imaging system; D-luciferin i.p.; bioluminescence quantification
Analysis Category: Protein Quantification; Methods: BCA assay; Steady-Glo luciferase assay
Parameter: Size (DMF); Result: ~60-70 nm
Parameter: Zeta potential (neutral lipid-PEGs); Result: ~+8 mV
Parameter: Zeta potential (anionic lipid-PEGs); Result: ~−7 mV
Parameter: siRNA encapsulation efficiency; Result: ~50-60%
Parameter: Surface lipid-PEG (μg/mg PLGA); Result: ~35-40 (similar across all types)
Lipid-PEG: Neutral
Lipid-PEG: DMG-PEG; Tails: C14:0 (saturated); k_d (h⁻¹): 0.52; t₁/₂ (h): 1.33; Dissociation Rate: Fastest
Lipid-PEG: DPG-PEG; Tails: C16:0 (saturated); k_d (h⁻¹): 0.21; t₁/₂ (h): 3.30; Dissociation Rate: Moderate
Lipid-PEG: DSG-PEG; Tails: C18:0 (saturated); k_d (h⁻¹): 0.025; t₁/₂ (h): 27.73; Dissociation Rate: Slowest
Lipid-PEG: Ceramide-PEG; Tails: C16:1 (unsaturated); k_d (h⁻¹): 1.05; t₁/₂ (h): 0.66; Dissociation Rate: Fastest
Lipid-PEG: Anionic
Lipid-PEG: DMPE-PEG; Tails: C14:0 (saturated); k_d (h⁻¹): 0.68; t₁/₂ (h): 1.02; Dissociation Rate: Fastest
Lipid-PEG: DPPE-PEG; Tails: C16:0 (saturated); k_d (h⁻¹): 0.17; t₁/₂ (h): 4.08; Dissociation Rate: Moderate
Lipid-PEG: DSPE-PEG; Tails: C18:0 (saturated); k_d (h⁻¹): 0.028; t₁/₂ (h): 24.76; Dissociation Rate: Slowest
Lipid-PEG: DOPE-PEG; Tails: C18:1 (unsaturated); k_d (h⁻¹): 0.33; t₁/₂ (h): 2.10; Dissociation Rate: Fast (unsaturated)
Lipid-PEG: Key trends; Tails: Longer/saturated tails → slower dissociation; k_d (h⁻¹): Unsaturation → faster dissociation; t₁/₂ (h): Charge (neutral vs. anionic) → negligible effect
Lipid-PEG: DMG-PEG; IC₅₀ (nM): Low; Ranking: Fast dissociation = better silencing
Lipid-PEG: DPG-PEG; IC₅₀ (nM): Low; Ranking: Fast dissociation = better silencing
Lipid-PEG: DSG-PEG; IC₅₀ (nM): High (poor); Ranking: Slow dissociation = poor in vitro silencing
Lipid-PEG: Ceramide-PEG; IC₅₀ (nM): Low; Ranking: Fast dissociation
Lipid-PEG: DMPE-PEG; IC₅₀ (nM): Low; Ranking: Fast dissociation
Lipid-PEG: DPPE-PEG; IC₅₀ (nM): Low; Ranking: Fast dissociation
Lipid-PEG: DSPE-PEG; IC₅₀ (nM): High (poor); Ranking: Slowest dissociation = poorest silencing
Lipid-PEG: DOPE-PEG; IC₅₀ (nM): Moderate; Ranking: Unsaturated = moderate
Lipid-PEG: Ceramide-PEG; t₁/₂: <20 min; AUC: Low; Circulation: Short
Lipid-PEG: DSG-PEG; t₁/₂: ~3.3 h; AUC: Moderate; Circulation: Moderate
Lipid-PEG: DPPE-PEG; t₁/₂: <20 min; AUC: Low; Circulation: Short
Lipid-PEG: DSPE-PEG; t₁/₂: ~6 h; AUC: ~68× naked siRNA; Circulation: Longest
Lipid-PEG: DOPE-PEG; t₁/₂: <20 min; AUC: Low; Circulation: Short
Lipid-PEG: Naked siRNA; Tumor Accumulation (vs. naked siRNA): 1× (baseline); Circulation t₁/₂: Rapid clearance
Lipid-PEG: Ceramide-PEG; Tumor Accumulation (vs. naked siRNA): 2.2×; Circulation t₁/₂: Short
Lipid-PEG: DSG-PEG; Tumor Accumulation (vs. naked siRNA): 4.7×; Circulation t₁/₂: Moderate
Lipid-PEG: DOPE-PEG; Tumor Accumulation (vs. naked siRNA): 5.0×; Circulation t₁/₂: Short
Lipid-PEG: DPPE-PEG; Tumor Accumulation (vs. naked siRNA): 6.1×; Circulation t₁/₂: Short
Lipid-PEG: DSPE-PEG; Tumor Accumulation (vs. naked siRNA): 14.5×; Circulation t₁/₂: Longest
Lipid-PEG: Naked siRNA; Luciferase Knockdown: Baseline; Circulation: -; Tumor Accumulation: Low
Lipid-PEG: Ceramide-PEG; Luciferase Knockdown: Insignificant; Circulation: Short; Tumor Accumulation: Low
Lipid-PEG: DSG-PEG; Luciferase Knockdown: ~50%; Circulation: Moderate; Tumor Accumulation: Moderate
Lipid-PEG: DPPE-PEG; Luciferase Knockdown: ~50%; Circulation: Short; Tumor Accumulation: Moderate
Lipid-PEG: DSPE-PEG; Luciferase Knockdown: ~40%; Circulation: Longest; Tumor Accumulation: Highest
Parameter: In vitro silencing vs. k_d; Finding: Positive correlation: Faster dissociation → better in vitro silencing
Parameter: Cellular uptake vs. k_d; Finding: Positive correlation: Faster dissociation → higher uptake (for saturated tails)
Parameter: PK vs. k_d; Finding: Negative correlation: Slower dissociation → longer circulation
Parameter: Tumor accumulation vs. t₁/₂; Finding: Positive correlation: Longer circulation → higher tumor accumulation
Parameter: In vivo silencing; Finding: DSPE-PEG (slowest dissociation) achieved best balance: 40% knockdown with 14.5× tumor accumulation
1. In vivo silencing modest: Only ~40-50% luciferase knockdown was achieved; complete or near-complete silencing would be desirable for therapeutic applications.
2. No therapeutic outcome: The study uses luciferase reporter knockdown as an efficacy readout, not tumor growth inhibition or survival benefit.
3. Non-targeted NPs: No active targeting ligand was included; the approach relies on passive targeting via the EPR effect, which may be insufficient for many tumor types.
4. Xenograft model only: Subcutaneous Luc-HeLa tumors in immunodeficient mice may not fully recapitulate the complexity of human tumors or the immune response.
5. Single siRNA cargo: Only luciferase siRNA was used; delivery of therapeutic siRNAs (e.g., targeting oncogenes) was not demonstrated.
6. Limited correlation for unsaturated lipid-PEGs: Ceramide-PEG and DOPE-PEG deviated from the positive correlation between k_d and cellular uptake, suggesting additional factors influence their behavior.
7. Lipid-PEG quantification method: The barium iodide method measures total PEG but cannot distinguish between surface-bound and free lipid-PEG; dissociation was inferred from loss of surface-associated lipid-PEG.
8. No mechanistic study of albumin binding: While albumin is proposed as the driver of de-PEGylation, the specific binding interactions were not characterized.
9. Short observation time for some NPs: NPs with fast dissociation (e.g., DMG-PEG, DMPE-PEG) fell below detection limits within 6-12 h; longer-term stability could not be assessed.
10. PEG length not varied: All lipid-PEGs used had 2 kDa PEG; the effect of PEG molecular weight on de-PEGylation was not studied.
11. In vitro vs. in vivo correlation limited: DSPE-PEG NPs showed poor in vitro silencing but achieved ~40% in vivo knockdown, suggesting in vitro data alone cannot predict in vivo efficacy.
12. Potential for PEG-related immune responses: Repeated dosing with PEGylated NPs can elicit anti-PEG antibodies; this was not assessed.
Report prepared based on the published Theranostics article. For full experimental details, supplementary figures, and complete references, please refer to the original publication.
Related articles
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programs with pharma, biotech and academic groups — from target selection through GMP supply.